Hospitals are still relying on fax machines and photocopies — and it’s costing you

The article argues that the U.S. health system is still burdened by fax machines and photocopies, and that AI and modern digital tools could materially improve efficiency. It is a broad opinion piece rather than a company-specific or market-moving event. The core message is constructive on healthcare technology adoption, but it contains no hard financial or operational figures.

Analysis

The investment signal here is not “healthcare digitization is good,” but that the largest near-term winners are the picks-and-shovels vendors that turn administrative friction into software spend. Revenue cycle, interoperability, identity verification, e-signature, claims automation, and workflow orchestration are the highest-conviction pockets because the ROI is measurable in weeks, not years, and buyers can justify spend from labor savings rather than clinical transformation. That makes this a more durable demand driver than many AI narratives: it is tied to cost takeout, which survives budget scrutiny even if broader healthcare IT capex slows.

The second-order effect is competitive compression for smaller providers and payers still running manual back offices. Organizations that can’t automate prior auth, referrals, eligibility, and document intake will carry structurally higher SG&A and slower cash conversion, which compounds into weaker margins and worse payer negotiations over 12-24 months. The real loser is not necessarily an incumbent software vendor, but the long tail of healthcare operators whose administrative overhead becomes visible once peers cut cost per claim and shorten days-in-A/R.

The contrarian view is that the market may be overestimating how fast analog process replacement happens in healthcare. Procurement is fragmented, integration risk is high, and compliance concerns can slow enterprise rollouts; that means this is a multi-year adoption curve, not a one-quarter re-rating story. The best setup is likely a barbell: own the software beneficiaries with proven workflow ROI, but avoid paying up for speculative AI names whose use cases depend on hospital system-wide rewiring rather than discrete automation wins.

Key Decisions for Investors

• Long sustained automation beneficiaries in healthcare IT on a 6-12 month horizon: workhorse workflow/revenue-cycle names such as VEEV and TYL on pullbacks; risk/reward is favorable because adoption is budget-funded and margin-accretive, with downside cushioned by recurring revenue.
• Pair trade: long a healthcare automation enabler basket (VEEV, DOCS, TWLO-like workflow infrastructure exposure if available) vs short a basket of administrative-intensive providers/payers with weaker execution; thesis is SG&A pressure and slower operating leverage over 12-24 months.
• Use call spreads rather than outright longs on any AI-enabled healthcare software name that has rerated on narrative alone; the adoption curve is long, so premium decay is the main risk if implementation timelines slip.
• If you want cleaner expression, buy small-cap revenue-cycle or claims automation names only after a post-earnings selloff; these names can rerate 15-25% on evidence of shorter sales cycles and land-and-expand traction, but they are volatile if hospital budgets wobble.
• Avoid shorting established enterprise healthcare software purely on the analog-to-digital theme; the more reliable trade is underweighting manual-process-heavy operators whose margin gap widens gradually, not betting on an immediate software displacement shock.